$1.42 Billion in Sales Expected for Clorox Co (NYSE:CLX) This Quarter

Brokerages predict that Clorox Co (NYSE:CLX) will announce $1.42 billion in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Clorox’s earnings, with the lowest sales estimate coming in at $1.42 billion and the highest estimate coming in at $1.44 billion. Clorox posted sales of $1.47 billion during the same quarter last year, which would indicate a negative year-over-year growth rate of 3.4%. The company is scheduled to report its next quarterly earnings results on Monday, February 3rd.

On average, analysts expect that Clorox will report full-year sales of $6.17 billion for the current fiscal year, with estimates ranging from $6.15 billion to $6.20 billion. For the next financial year, analysts forecast that the company will post sales of $6.38 billion, with estimates ranging from $6.28 billion to $6.62 billion. Zacks’ sales averages are a mean average based on a survey of analysts that cover Clorox.

Clorox (NYSE:CLX) last released its earnings results on Thursday, October 31st. The company reported $1.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.54 by $0.05. Clorox had a net margin of 13.20% and a return on equity of 123.56%. The company had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.51 billion. During the same quarter in the previous year, the company earned $1.62 EPS. Clorox’s quarterly revenue was down 3.6% compared to the same quarter last year.

CLX has been the topic of several research reports. Barclays set a $138.00 price objective on shares of Clorox and gave the stock a “sell” rating in a report on Friday, November 1st. Morgan Stanley restated an “underweight” rating and set a $134.00 price objective (down previously from $144.00) on shares of Clorox in a report on Monday, September 30th. Bank of America lowered their price objective on shares of Clorox from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, October 3rd. Credit Suisse Group lowered their price objective on shares of Clorox from $172.00 to $168.00 and set an “outperform” rating on the stock in a report on Thursday, October 3rd. Finally, Citigroup lowered their price objective on shares of Clorox from $167.00 to $163.00 and set a “neutral” rating on the stock in a report on Thursday, October 3rd. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $152.17.

Shares of Clorox stock traded up $0.13 during trading on Monday, reaching $152.26. 1,001,889 shares of the company traded hands, compared to its average volume of 995,149. The company has a debt-to-equity ratio of 4.69, a current ratio of 0.87 and a quick ratio of 0.52. Clorox has a 1-year low of $143.58 and a 1-year high of $166.90. The company has a 50 day moving average price of $148.45 and a 200-day moving average price of $153.92. The firm has a market capitalization of $19.17 billion, a PE ratio of 24.09, a P/E/G ratio of 4.88 and a beta of 0.38.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 29th will be paid a $1.06 dividend. The ex-dividend date of this dividend is Tuesday, January 28th. This represents a $4.24 annualized dividend and a dividend yield of 2.78%. Clorox’s payout ratio is 67.09%.

In related news, SVP Denise Garner sold 725 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $146.34, for a total transaction of $106,096.50. Following the completion of the transaction, the senior vice president now owns 5,805 shares in the company, valued at $849,503.70. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Andrew J. Mowery sold 5,648 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $146.29, for a total transaction of $826,245.92. Following the transaction, the senior vice president now owns 15,920 shares of the company’s stock, valued at approximately $2,328,936.80. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of CLX. Heritage Wealth Advisors bought a new position in Clorox during the second quarter valued at about $30,000. Strategic Blueprint LLC bought a new position in Clorox during the third quarter valued at about $37,000. Transamerica Financial Advisors Inc. bought a new position in Clorox during the second quarter valued at about $41,000. Usca Ria LLC bought a new position in Clorox during the third quarter valued at about $41,000. Finally, Mirova bought a new position in Clorox during the second quarter valued at about $47,000. Institutional investors own 77.67% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Recommended Story: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.